2023-06-01 16:02
Biovica, active in cancer diagnostics, today announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world’s largest cancer conference, the annual ASCO meeting, on Sunday, June 4. The data supports...
2023-05-17 21:00
Biovica today announces that Biovica Inc, the US laboratory and subsidiary of Biovica International AB, has signed a provider contract with MediNcrease Health Plans, a US, national provider network and provider advocacy firm, to make Biovica’s blood...
2023-05-17 14:15
The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 May 2023 and the following resolutions were passed by the meeting. EMPLOYEE STOCK OPTION PROGRAM 2023/2026 FOR SENIOR EXECUTIVES...
2023-04-27 14:30
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Wednesday 17 May 2023, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at...
2023-03-28 08:00
Biovica, active in cancer monitoring, today announces that the company has signed a commercial partnership with the European distributor TOROMEDICAL group for the commercialization of the DiviTumTKa test for clinical routine use in the Netherlands and...
2023-03-16 08:00
2023-03-13 16:00
The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2023-02-08 08:00
Biovica, active in cancer monitoring, today announces that the company’s test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market. “The CLIA certification...
2023-01-31 09:00
Biovica, active in cancer diagnostics, today announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers. The results, from an analysis of samples and clinical data from the SWOG S0226...
>4,500
Numbers of patients in studies
25+
Publications
10
Pharma Contracts